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Abstract
Background—The 21-gene Recurrence Score (RS) predicts outcome and benefit from adjuvant 
chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the 
NSABP B-28 study, we evaluated the 21-gene Recurrence Score (RS) for its prognostic impact 
and its ability to predict benefit from paclitaxel (P) in node-positive, estrogen receptor-positive 
(ER+) breast cancer patients treated with adjuvant chemotherapy plus tamoxifen.
Methods—The B-28 trial compared doxorubicin/cyclophosphamide (AC) with AC followed by P 
in 3060 patients. Tamoxifen for 5 years was also given to patients ≥50 years and those <50 years 
with ER+ and/or progesterone receptor-positive (PR+) tumors. The present study includes 1065 
ER-positive, tamoxifen-treated patients with RS assessment. Median follow-up time was 11.2 
years.
Results—In univariate analyses RS was a significant predictor of outcome. In multivariate 
analyses, RS remained a significant independent predictor of outcome beyond clinico-pathologic 
factors, age, and type of surgery (p<0.001). In the study population (n=1065), the disease-free 
survival (DFS) hazard ratio (HR) with adding P to AC was 0.87 (95% CI=0.72–1.05; P=0.14). RS 
was not a significant predictor of P benefit: for DFS, HRs for adding P to AC in RS low, 
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intermediate, and high subgroups were 1.01 (95% CI=0.69–1.47; P=0.99), 0.84 (95% CI=0.62–
1.14; P=0.26), and 0.81 (95% CI=0.60–1.10; P=0.21), respectively (interaction P=0.64). Similar 
findings were observed for the other study endpoints.
Conclusions—RS maintains significant prognostic impact in ER-positive, node-positive patients 
treated with adjuvant chemotherapy plus tamoxifen. However, RS did not significantly predict 
benefit from adding paclitaxel to AC chemotherapy.
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Breast Cancer; Node-Positive; Prognosis and Prediction; Recurrence Score
Introduction
Gene expression profiling is useful for assessing risk of distant recurrence in patients with 
early-stage breast cancer and provides additional information to that obtained from 
traditional histopathologic factors and biomarkers [1–6]. Several gene expression signatures 
predict risk of distant recurrence in untreated patients and those treated with hormonal 
therapy and/or chemotherapy [1–7]. The 21-gene Recurrence Score (RS) Assay (Oncotype 
DX®) quantifies the risk of distant recurrence in node-negative and node-positive, estrogen 
receptor (ER)-positive breast cancer patients treated with adjuvant endocrine therapy [5–8]. 
There are limited data on the prognostic impact of RS in node-positive patients treated with 
adjuvant chemo-endocrine therapy [9].
Besides its prognostic ability, the RS was also shown to significantly predict benefit from 
adding non-anthracycline-based chemotherapy to endocrine therapy in node-negative, ER-
positive patients (NSABP B-20 trial) [10] and from adding anthracycline-based 
chemotherapy to endocrine therapy in postmenopausal, node-positive, ER-positive patients 
(SWOG 8814 trial) [10,11]. In both studies, patients with high RS significantly benefited 
from adding chemotherapy, whereas patients with intermediate or low RS did not. No study 
to date has formally evaluated the role of RS in predicting benefit from adding a taxane to an 
anthracycline-based regimen.
We sought to evaluate the prognostic impact of RS on residual risk of recurrence and death 
in node-positive, ER-positive patients treated with adjuvant chemo-endocrine therapy in the 
NSABP B-28 trial [12] and to also evaluate whether the RS predicts benefit from adding 
paclitaxel to AC chemotherapy.
Patients and Methods
The NSABP B-28 Trial
The NSABP B-28 trial evaluated whether the sequential addition of four cycles of paclitaxel 
(P: 225 mg/m2 every 3 weeks) to 4 cycles of doxorubicin/cyclophosphamide (AC every 3 
weeks) would improve disease-free survival (DFS) and overall survival (OS) compared to 4 
cycles of AC alone in patients with resected operable, node-positive breast cancer. Between 
August 1995 and May 1998, 3,060 patients were randomly assigned (AC: 1,529 patients and 
AC→P: 1,531 patients). Patients ≥50 years and those <50 with estrogen receptor (ER)-or 
Mamounas et al. Page 2
Breast Cancer Res Treat. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
progesterone receptor (PR)-positive tumors also received tamoxifen for 5 years starting with 
the first dose of AC. Post-lumpectomy radiotherapy was mandated. Post-mastectomy or 
regional-nodal radiotherapy was prohibited.
Aims, Eligibility, and Endpoints for the Present Study
The aims of the present study were to evaluate the prognostic impact of RS on DFS, distant 
recurrence-free interval (DRFI), OS, and breast cancer-specific survival (BCSS), and to 
examine the independent prognostic contribution of RS beyond traditional clinico-pathologic 
factors such as age, tumor size, grade, number of positive nodes, and adjuvant chemotherapy 
assignment. In addition, we sought to examine the association between RS and benefit from 
the sequential addition of P to AC chemotherapy.
Eligible patients had to be ER-positive by immunohistochemistry (IHC) on tissue 
microarray, tamoxifen-treated, and with successful 21-gene RS assay assessment. The 
primary pre-specified endpoint was DFS, defined as time from study entry to first loco-
regional or distant recurrence, contralateral breast cancer, non-breast second primary cancer, 
or death from other causes. Other endpoints included DRFI, defined as time from study 
entry to first distant recurrence, with contralateral breast cancer or non-breast second 
primary cancers ignored, and deaths before distant recurrence considered as censoring 
events; OS; and BCSS, defined as time from study entry to death from breast cancer.
RNA Assessment Methodology for the Present Study
Available tumor specimens from B-28 that met the above eligibility criteria were centrally 
evaluated for histologic grade using the modified Bloom-Richardson score using 5-micron 
tissue sections stained by hematoxylin and eosin (H&E) [13]. All specimens were then 
analyzed for the Oncotype DX™ Recurrence Score as previously described [5,14,15]. Three 
5-micron-thick sections were cut by the NSABP Division of Pathology laboratory. After 
sectioning, tumor-rich area in the tumor block was marked by the Genomic Health, Inc. 
(GHI) pathologist using H&E-stained sections as references. The tumor-rich area was 
manually micro-dissected with clean blades and RNA was extracted according to standard 
operating procedures for the Oncotype DX assay. The RNA was then assessed for quantity 
(Ribogreen assay™ Molecular Probes/Invitrogen Eugene, OR) and residual genomic DNA 
(using a DNA-specific PCR assay). RNA was subjected to reverse transcription (RT) with a 
universal RNA (Stratagene, Agilent, Santa Clara, CA) as a positive control and water as a 
negative control for each set of RT reactions followed by quantitative polymerase chain 
reaction analysis. The average reference gene expression served as a quality metric for each 
sample, and the limit of detection and limit of quantitation cutoffs and other quality metrics, 
as defined for the 21-gene assay, was applied as appropriate for the 21 genes in the RS [15]. 
In the end, the Oncotype DX assay was successfully performed in 1,065 patients with 
follow-up.
Statistical Methodology for the Present Study
Patients were grouped into low RS (<18), intermediate RS (18–30), and high RS (≥31). 
Kaplan-Meier estimates and log-rank tests were used to evaluate outcomes in different RS 
risk groups. Univariate Cox models were used to assess the strength of the association 
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between RS and outcomes. Multivariate Cox proportional hazards models were used to 
examine whether RS provides independent prognostic information in addition to clinico-
pathologic factors and whether the RS predicts benefit from the addition of adjuvant P to AC 
chemotherapy. Time-dependent Cox proportional hazards models were also used to explore 
whether or not the association between RS and risk of cancer recurrence varied over time. A 
P value <0.05 for the likelihood ratio test was used to determine the statistical significance 
of findings.
The study was approved by the Essex (NJ), Aultman Hospital (OH), and University of 
Pittsburgh IRBs (PA). Written, informed consent was obtained from all participants.
Results
Results of the Parent B-28 Trial
The results of the NSABP B-28 trial were first reported in 2005 [12] and demonstrated that 
the addition of P to AC significantly reduced the hazard for DFS event by 17% (Relative risk 
[RR]: 0.83, 95% CI: 0.72–0.95, P=0.006). Five-year DFS was 76%± 2% for patients 
randomly assigned to AC→P compared to 72%± 2% for those assigned to AC. 
Improvement in OS was small and not statistically significant (RR: 0.93, 95% CI: 0.78–1.12, 
P=0.46). Five-year OS was 85% ± 2% for both groups. Subset analysis of the effect of P 
according to hormone receptors or tamoxifen administration did not reveal statistically 
significant interaction (DFS: P=0.30; OS: P=0.44, respectively).
Patient Population for the Current Study
Of the 3060 patients participating in the B-28 trial, 1945 were excluded because they had 
either ER-negative tumors or tumor block was not available. An additional 32 patients were 
excluded for various reasons (8 were clinically ineligible, 17 did not receive tamoxifen, and 
7 received post-mastectomy radiotherapy). Of the remaining 1083 tumors processed by GHI, 
11 had insufficient RNA and 7 had poor qRT-PCR sample quality, leaving 1065 patients 
constituting the core group for the present study. Median follow up was 11.2 years.
Comparison of Included versus Excluded ER-Positive B-28 Patients
Among 1995 patients who were not included in this study, 999 had ER-positive tumors 
according to assessment from the participating institutions. When the 1065 B-28 ER-positive 
patients included in the present study were compared to the 999 ER-positive B-28 patients 
who were excluded, there were no significant differences in the distribution of age, number 
of positive nodes, or treatment group (AC or AC→P) (Supplementary Table 1). Compared to 
excluded patients, those who were included were significantly more likely to have 
undergone mastectomy (P=0.007), have larger tumors (P<0.001), and have higher grade 
tumors (P=0.004, Supplementary Table 1). When outcomes of the 1,065 patients who were 
included in the study were compared to those 999 ER-positive patients who were excluded, 
the former group of patients tended to have worse outcomes compared to the latter (DFS: 
61.1 % vs. 66.5%, P=0.014; DRFI: 68% vs. 71.9%, P=0.04, respectively. Figure 1).
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Distribution of the Recurrence Score in the Study Population
Among the 1065 patients included in the present study, 386 (36%) had a low RS (<18), 364 
(34%) had an intermediate RS (18–30), and 315 (30%) had a high RS (≥31). The 
distribution of the RS was not statistically significantly different according to treatment, 
surgery type, or number of positive nodes. However, there were statistically significant 
differences in the distribution of RS according to age and tumor size, with older patients and 
those with small tumors being more likely to have low RS, although a wide distribution of 
RS values was seen in each age or size category (data not shown).
Univariate Analysis of Outcomes According to Recurrence Score Categories
In univariate analyses the RS was a statistically significant predictor of outcome for all four 
endpoints (DFS, DRFI, OS, and BCSS) (Figure 2A, 2B, 2C, and 2D, respectively). DFS at 
10 years was 75.8% for patients with low RS compared to 57% for those with intermediate 
RS, and was 48% in those with high RS (log rank p<0.001); the percent distant relapse-free 
was 80.9%, 64.9%, and 55.8%, respectively (p<0.001); OS was 90%, 74.7%, and 63%, 
respectively (p<0.001); and breast cancer-specific survival was 95%, 78.9%, and 68.2%, 
respectively (p<0.001).
Multivariate Analysis of Outcomes Adjusted for Clinico-pathologic Variables
The RS was an independent predictor of outcome on multivariate analysis (Table 1). 
Multivariate Cox proportional hazards models adjusting for treatment, age, number of 
positive nodes, type of surgery, tumor size, and tumor grade demonstrated a hazard ratio 
(HR) associated with a 50-unit increment in RS of 2.53 (95% CI=1.90, 3.38; p<0.001). 
(Table 1). Additional independent predictors on multivariate analysis included treatment 
(HR: 0.81; 95% CI=0.67, 0.99; P=0.037), number of positive nodes (HR: 1.82; 95% 
CI=1.49, 2.23), and tumor size (cm) (HR: 1.13 (95% CI=1.03, 1.23). The RS was also a 
significant independent predictor of outcome for the remaining three endpoints. The adjusted 
HRs corresponding to DRFI, OS, and BCSS were 2.42, 3.09, and 3.38, respectively. The 
likelihood ratio test p-values were all <0.001. The association of the RS with the risk of a 
DFS event was strongest in the first 5 years: up to 5 years, the adjusted HR associated with a 
50-unit increment was 3.81 (95% CI=2.67, 5.43; P<0.001), whereas after 5 years the 
adjusted HR was 1.39 (95% CI=0.88, 2.19; P=0.16). Similar patterns were seen for the other 
endpoints.
Prognostic Impact of Recurrence Score across Various Patient Subgroups
The RS was a significant predictor of outcome (for all four endpoints) in various patient 
subgroups defined by treatment (AC or AC→P), type of surgery (lumpectomy or 
mastectomy), number of positive nodes (1–3 positive nodes or 4+ positive nodes), age at 
study entry (<50 or ≥ 50 years-old), and tumor size (0–2 cm or ≥2.1 cm) (Table 2). Notably 
among 268 patients with 1–3 positive nodes and low RS, only 20% had a DFS event (Figure 
3A) and only 2% had died from breast cancer at 10 years (Figure 3C). Generally, outcomes 
of patients with 4 or more positive nodes and a low RS were as good as or better than those 
of patients with 1–3 positive nodes and intermediate or high RS. (Figure 3A, 3B, 3C, and 
3D).
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Predictive Impact of Recurrence Score on Treatment Benefit from Addition of Paclitaxel to 
AC
Among 2007 B-28 patients with ER-positive tumors, as assessed by participating 
institutions, the addition of P to AC only improved risk of a DFS event marginally 
(HR=0.86; 95% CI=0.75, 0.99; P=0.04). Among the 1065 node-positive, ER-positive 
patients with RS information, a similar magnitude of treatment effect was observed but the 
difference was not statistically significant (HR=0.87; 95% CI=0.72, 1.05; P=0.14). For DFS, 
the HRs associated with the addition of P in RS low, intermediate, and high subsets were 
1.01 (95% CI=0.69, 1.47; P=0.99), 0.84 (95% CI=0.62, 1.14; P=0.26), and 0.81 (95% 
CI=0.60, 1.10; P=0.21), respectively. The likelihood ratio test for interaction between P and 
RS risk groups did not suggest differential treatment effect across RS risk groups (P=0.65). 
Similar results were obtained for the other three endpoints (Figure 4) and when the subset of 
937 patients who were assessed to be HER-2 negative or equivocal by RT-PCR was 
examined (data not shown).
Discussion
We have demonstrated that the 21-gene RS is a significant and independent predictor of 
outcome in node-positive, ER-positive breast cancer patients treated with adjuvant chemo-
endocrine therapy. These results build on the previous experience on the prognostic impact 
of RS in node-negative patients treated with no adjuvant therapy, adjuvant endocrine therapy, 
or adjuvant chemo-endocrine therapy, as well as those in node-positive patients treated with 
adjuvant endocrine therapy alone [5,10,11]. Only one study (ECOG E2197) [9] has thus far 
evaluated the prognostic impact of the RS in node-positive breast cancer patients (≤3 
positive nodes) treated with adjuvant chemo-endocrine therapy. In that study the RS was 
found to be independently prognostic in a cohort of 465 ER-positive patients with 0–3 
positive nodes treated with AC or AT chemotherapy. Our study confirms those findings and 
expands the prognostic impact of RS to patients with ≥4 positive nodes. Our findings have 
potential clinical implications by refining residual risk of recurrence and death in node-
positive, ER-positive patients and they can be useful in tailoring the extent of adjuvant 
chemotherapy and can help to identify patients with significant residual risk who could be 
candidates for clinical research protocols evaluating novel adjuvant therapies.
Our findings on the prognostic effect of RS according to the number of positive nodes 
suggest that the RS had a large, independent impact on prognosis within nodal subgroups. In 
fact, patients with ≥4 positive nodes and low RS had outcomes as good as or better than 
patients with 1–3 positive nodes and intermediate or high RS. This was true for all endpoints 
evaluated. These findings are in concordance with those reported from previous studies in 
node-positive patients treated with endocrine therapy alone [6,9,16] and underscore the 
complementary prognostic contribution of the RS in the context of the traditional clinico-
pathologic prognostic factors.
The addition of taxanes to anthracycline-based chemotherapy regimens has resulted in a 
modest but statistically significant reduction in the odds of recurrence and death 
(approximately 15–20%) [12,17–19]. This reduction has translated to a small absolute 
improvement in DFS and OS (approximately 4–5%). Thus, the majority of patients who 
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receive taxanes do not benefit from such treatment. Furthermore, the CALGB 9344 trial [19] 
demonstrated less benefit from the sequential addition of P to AC chemotherapy in patients 
with ER-positive tumors compared to those with ER-negative tumors. A similar benefit was 
observed in the parent NSABP B-28 trial in terms of recurrence-free survival, although no 
significant interaction between receptor status and treatment effect was observed.
Several investigators have attempted to identify predictors of taxane benefit with 
inconsistent results. Hayes et al. [19] examined the effect of ER, PR, and HER2 status in 
predicting benefit from adding P to AC in a subset of node-positive breast cancer patients 
who participated in the CALGB 9344 trial. Patients with a HER2-positive breast cancer 
benefited from P, regardless of ER status, but P did not benefit patients with HER2-negative, 
ER-positive cancers. Hugh et al. [20] investigated the predictive significance of tumor 
subtyping by IHC (for ER/PR/HER2 and Ki67) on the relative benefit from docetaxel in the 
BCIRG 001 trial, which compared TAC (docetaxel, doxorubicin, cyclophosphamide) versus 
FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in patients with node-positive breast 
cancer. Patients were classified by tumor characteristics as (1) triple negative (ER/PR/
HER2–negative, 14.5%), (2) HER2 (HER2-positive, ER/PR-negative, 8.5%), (3) luminal B 
(ER-positive and/or PR-positive and either HER2-positive and/or Ki67high, 61.1%), and (4) 
luminal A (ER-positive and/or PR-positive and not HER2-positive or Ki67high, 15.9%). 
Results demonstrated improved 3-year DFS with TAC versus FAC in the luminal B group 
(P=.025) and in a combined ER-positive/HER2-negative group treated with tamoxifen (P=.
041), with a marginal trend in triple negative (P=.051) and HER2 (P=.068) subtypes. 
However, no DFS advantage was seen in the luminal A population.
The above data suggest that the benefit from adding taxanes to an anthracycline-containing 
regimen appears smaller for patients with ER-positive tumors. Even within that group, there 
is possibly another subset that may not benefit at all from the addition of the taxane. 
Although we did not observe significant interaction between treatment and RS for adding P 
to AC, our findings in the low RS group are not inconsistent with those from prior studies 
showing no benefit from the addition of adjuvant chemotherapy to endocrine therapy in 
patients with low RS. However, contrary to prior reports demonstrating significant benefit 
from adding chemotherapy to endocrine therapy in patients with high RS [10,11], our 
findings did not demonstrate such significant benefit from adding P to AC in patients with 
high RS. One possible explanation for the lack of a significant treatment by RS interaction is 
that the overall benefit from adding P to AC was modest not only in the B-28 ER-positive 
cohort (HR: 0.86) but also in the ER-positive cohort with RS information, which may have 
diminished the power to detect a significant treatment by RS interaction. In addition, the 
large benefit from adjuvant AC in patients with high RS may have minimized any additional 
benefit from the addition of P. Although inconclusive, the HRs of treatment effect from the 
addition of P to AC in patients with intermediate or high RS do not rule out a modest 
chemotherapy effect. The observation of possible treatment effect in patients with 
intermediate RS with the addition of a taxane to AC may have biologic implications, if 
confirmed in other datasets. To that end, the results of the TAILORx trial [21] on the effect 
of adjuvant chemotherapy in patients with RS of 11–25 are eagerly awaited, particularly 
because a considerable proportion of the patients randomly assigned to chemo-endocrine 
therapy in that trial have been treated with a taxane-containing regimen.
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In conclusion, our results demonstrate a significant prognostic contribution of the 
Recurrence Score in node positive, ER-positive patients treated with chemo-endocrine 
therapy but no significant treatment by RS interaction. Our findings could help to identify 
subgroups of patients with low residual risk of recurrence, which could be adequately treated 
with shorter adjuvant chemotherapy regimens and may not necessarily need the addition of a 
taxane. Alternatively, they could also help to identify patients with considerable residual risk 
of recurrence who could be candidates for longer adjuvant chemotherapy regimens and for 
participation in adjuvant trials evaluating novel agents.
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Fig. 1. 
Comparison of (A) disease-free survival (DFS) and (B) distant relapse-free interval (DRFI) 
between 1,065 ER-positive, B-28 patients who were included in the present study and 999 
ER-positive, B-28 patients who were excluded.
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Fig. 2. 
Kaplan-Meier curves for (A) disease-free survival (DFS), (B) distant relapse-free interval 
(DRFI), (C) overall survival (OS), and (D) breast cancer-specific survival (BCSS) according 
to Recurrence Score categories: NSABP B-28
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Fig. 3. 
Kaplan-Meier curves for disease-free survival (DFS) according to Recurrence Score 
categories: NSABP B-28
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Fig. 4. 
Forest Plots of the effect of paclitaxel (P) according to Recurrence Score (RS) category: 
NSABP B-28
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Table 1
Multivariate Cox proportional hazards model for disease-free survival excluding and including the Recurrence 
Score (RS): NSABP B-28
Excluding RS Including RS
HR (lower 95% CI, upper 95% CI) P HR (lower 95% CI upper 95% CI), P
Recurrence Score* NA NA 2.53 (1.90,3.38) <0.001
Treatment 0.83 (0.69,1.01) 0.060 0.81 (0.67,0.99) 0.037
Age ≥ 50 0.96 (0.79,1.17) 0.687 1.00 (0.82,1.22) 0.967
≥4 positive nodes 1.79 (1.47,2.19) <0.001 1.82 (1.49,2.23) <0.001
Mastectomy 1.23 (1.01,1.51) 0.042 1.18 (0.97,1.45) 0.105
Tumor size (cm)* 1.13 (1.04,1.23) 0.005 1.13 (1.03,1.23) 0.007
Moderate grade 1.57 (1.08,2.30)
<0.001
1.42 (0.97,2.08)
0.133
Poor grade 1.95 (1.33,2.86) 1.46 (0.98,2.16)
*
Recurrence Score hazard ratio (HR) is associated with a 50 point difference. Tumor size HR is associated with a 1 cm difference.
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